Introduction Abbott has four reportable segments: Established Pharmaceuticals, Diagnostics, Nutritional Products, and Medical Devices. Asset Structure Analysis Abbott’s total assets were $73.2 billion as of December 31, 2023, down from $74.4 billion as of December 31, 2022. Abbott’s asset structure as of December 31, 2023 Deferred income saxes and other assets were $7.1 billion, accounting…
Pharmaceutical
Your Pharmaceutical category
Viatris(VTRS) 2023 and Q1 2024 Financial Analysis, and Stock Valuation
Asset Structure Analysis Viatris’ total assets were $47.7 billion as of December 31, 2023, down from $50 billion as of December 31, 2022. Intangible assets, net were $19.2 billion as of December 31, 2023, accounting for 40.3% of total assets. Goodwill was $9.9 billion as of December 31, 2023, making up 20.8% of total assets….
Phibro Animal Health(PAHC) 2023 and Q3 2024 Financial Analysis, and Stock Valuation
Assets structure analysis Phibro Animal Health’s total assets were $971.4 million and $931.7 million as of June 30, 2023 and June 30, 2022, respectively. As of June 30, 2023, the company had cash and cash equivalents of $41.3 million, short-term investments of $40 million, accounts receivable, net of $163.5 million, other current assets of $63.4…
Pfizer(PFE) 2023 Financial Analysis and Stock Valuation
Assets condition analysis Pfizer’s total assets were $226.5 billion as of December 31, 2023, a increase of 14.9%, compared with $197.2 billion as of December 31, 2022. Identifiable intangible assets were $64.9 billion and $43.4 billion as of December 31, 2023 and December 31, 2022, respectively. Goodwill was $67.8 billion and $51.4 billion as of…
Bristol-Myers Squibb(BMY)Q1 2024
At April 25, 2024, Bristol-Myers Squibb released quarterly report for quarter ending march 31, 2024. Bristol-Myers Squibb’s total revenues were $11.9 billion and $11.3 billion in Q1 2024 and Q1 2023, respectively. The increase in total revenues was flat. Net earnings were -$11.9 billion and $2.27 billion in Q1 2024 and Q1 2023, respectively. Why…
Teva pharmaceutical(TEVA) 2023 Financial Analysis and Stock Valuation
Asset structure analysis Teva pharmaceutical ‘s total assets were $43.5 billion and $44 billion at December 31, 2023 and at December 31, 2022, respectively. Goodwill was $17.2 billion as of December 31, 2023, accounting for 39.5% of total assets. We think that goodwill is cost. Property, plant and equipment, net were $5.75 billion as of…
Biogen(BIIB):Analysis of Financial Statement for 2022 and for Q3 2023
Introduction Biogen(BIIB) is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. Biogen(BIIB) have a broad portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and co-developed two treatments to address a defining…
Sanofi(SNY): financial analysis for 2022 and Q3 2023.
Summary We reckon Sanofi(SNY) is worth €115 billion or $125.3 billion. Introduction Sanofi(SNY) is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Sanofi(SNY) has three principal activities: Pharmaceuticals, Consumer Healthcare, and Vaccines. Pharmaceuticals segment have €30.69 billion, consumer healthcare segment have €5.08…
Bristol-Myers Squibb Company(BMY)：$50 per share is a good buying opportunity
Bristol-Myers Squibb(BMY)Q1 2024 Introduction Bristol-Myers Squibb Company(BMY) continues to operate in one segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Bristol-Myers Squibb Company’ revenues come from products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. Profitability analysis Bristol-Myers Squibb Company(BMY) reported $46.1…
AstraZeneca PLC(AZN): 2022 financial report and Q3 2023 earnings analysis
AstraZeneca PLC(AZN) in fiscal 2022 has six reportable products sales: Oncology($14.6 billion ), Cardiovascular, Renal & Metabolism($9.18 billion ), Respiratory & Immunology($5.76 billion ), Vaccines & Immune Therapies($4.7 billion ), Rare Disease ($7 billion )and other($1.6 billion ). Profitability analysis AstraZeneca PLC(AZN) reported total revenues of $44.3 billion, $37.4 billion and $26.6 billion in 2022,in…